These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9987146

  • 1. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.
    Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R.
    Vaccine; 1999 Jan; 17(2):126-33. PubMed ID: 9987146
    [Abstract] [Full Text] [Related]

  • 2. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides.
    Fattom A, Li X, Cho YH, Burns A, Hawwari A, Shepherd SE, Coughlin R, Winston S, Naso R.
    Vaccine; 1995 Oct; 13(14):1288-93. PubMed ID: 8585282
    [Abstract] [Full Text] [Related]

  • 3. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein.
    Michon F, Fusco PC, Minetti CA, Laude-Sharp M, Uitz C, Huang CH, D'Ambra AJ, Moore S, Remeta DP, Heron I, Blake MS.
    Vaccine; 1998 Nov; 16(18):1732-41. PubMed ID: 9778749
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Vaccine; 2000 Nov 22; 19(7-8):850-61. PubMed ID: 11115709
    [Abstract] [Full Text] [Related]

  • 6. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.
    Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB.
    Infect Immun; 1993 Mar 22; 61(3):1023-32. PubMed ID: 8432585
    [Abstract] [Full Text] [Related]

  • 7. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
    Gupta RK, Anderson R, Cecchini D, Rost B, Griffin P, Benscoter K, Xu J, Montanez-Ortiz L, Siber GR.
    Dev Biol Stand; 1996 Mar 22; 86():283-96. PubMed ID: 8785957
    [Abstract] [Full Text] [Related]

  • 8. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S, Lo Surdo P, Tontini M, Proietti D, Zambonelli C, Bottomley MJ, Biagini M, Berti F, Costantino P, Romano MR, Study Group.
    Vaccine; 2015 Jan 03; 33(2):314-20. PubMed ID: 25448110
    [Abstract] [Full Text] [Related]

  • 9. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
    Ho MM, Bolgiano B, Martino A, Kairo SK, Corbel MJ.
    Hum Vaccin; 2006 Jan 03; 2(3):89-98. PubMed ID: 17012902
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL.
    J Infect Dis; 1999 Jan 03; 179(1):142-50. PubMed ID: 9841833
    [Abstract] [Full Text] [Related]

  • 11. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.
    Dagan R, Goldblatt D, Maleckar JR, Yaïch M, Eskola J.
    Infect Immun; 2004 Sep 03; 72(9):5383-91. PubMed ID: 15322036
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
    Gupta RK, Anderson R, Cecchini D, Rost B, Xu J, Gendreau K, Saroff DL, Marchant C, Siber GR.
    Biologicals; 1999 Jun 03; 27(2):167-76. PubMed ID: 10600208
    [Abstract] [Full Text] [Related]

  • 13. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
    An SJ, Yoon YK, Kothari S, Kothari N, Kim JA, Lee E, Kim DR, Park TH, Smith GW, Carbis R.
    Vaccine; 2011 Oct 13; 29(44):7618-23. PubMed ID: 21843575
    [Abstract] [Full Text] [Related]

  • 14. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H.
    Lancet; 2011 Oct 13; 348(9043):1688-92. PubMed ID: 8973430
    [Abstract] [Full Text] [Related]

  • 15. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B, Wald E, Guerra N, Byers C.
    Pediatrics; 1990 Apr 13; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [Abstract] [Full Text] [Related]

  • 16. Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
    Bröker M, Berti F, Schneider J, Vojtek I.
    Vaccine; 2017 Jun 05; 35(25):3286-3294. PubMed ID: 28487056
    [Abstract] [Full Text] [Related]

  • 17. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.
    Baraldo K, Mori E, Bartoloni A, Norelli F, Grandi G, Rappuoli R, Finco O, Del Giudice G.
    Infect Immun; 2005 Sep 05; 73(9):5835-41. PubMed ID: 16113302
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.
    Infect Immun; 1999 Nov 05; 67(11):5806-10. PubMed ID: 10531232
    [Abstract] [Full Text] [Related]

  • 19. Glycoconjugate vaccines and immune interference: A review.
    Dagan R, Poolman J, Siegrist CA.
    Vaccine; 2010 Aug 02; 28(34):5513-23. PubMed ID: 20600514
    [Abstract] [Full Text] [Related]

  • 20. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
    An SJ, Yoon YK, Kothari S, Kim DR, Kim JA, Kothari N, Lee E, Park TH, Carbis R.
    Vaccine; 2012 Feb 01; 30(6):1023-8. PubMed ID: 22192846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.